Annual report pursuant to Section 13 and 15(d)

Strategic Alliances (Details)

v3.10.0.1
Strategic Alliances (Details) - USD ($)
1 Months Ended 12 Months Ended 15 Months Ended 48 Months Ended
Oct. 12, 2017
Jul. 31, 2018
May 31, 2016
Jan. 31, 2015
Dec. 31, 2010
Dec. 31, 2018
Dec. 31, 2017
Dec. 31, 2016
Dec. 31, 2018
Dec. 31, 2018
Mar. 31, 2013
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                      
Initial upfront payment $ 6,000,000                    
Milestone revenue recognized                 $ 0    
Contract liability           $ 91,100,000 $ 152,300,000   91,100,000 $ 91,100,000  
Deferred revenue, current           63,503,000 56,883,000   63,503,000 63,503,000  
Deferred revenue, noncurrent           27,566,000 95,450,000   27,566,000 27,566,000  
Vifor Fresenius Medical Care Pharma Ltd | Development and License Agreement                      
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                      
Proceeds from license fees received     $ 50,000,000                
Vifor Fresenius Medical Care Pharma Ltd | Regulatory Milestones                      
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                      
Additional milestone payment   $ 2,000,000.0                  
Milestone payments, maximum     35,000,000                
Vifor Fresenius Medical Care Pharma Ltd | Launch and Sales-based Milestones                      
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                      
Milestone payments, maximum     195,000,000                
Vifor Fresenius Medical Care Pharma Ltd | Exclusive Option                      
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                      
Milestone payments, maximum     $ 555,000,000                
Pfizer | Collaborative Arrangement, Product                      
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                      
Milestone revenue recognized                   0  
Milestone payments, maximum       $ 275,000,000.0              
Non-refundable upfront payment       295,000,000.0   295,000,000.0          
Additional milestone payment to be received       275,000,000.0              
Contract liability           83,100,000     $ 83,100,000 $ 83,100,000  
Tesaro                      
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                      
Milestone payments, maximum         $ 85,000,000.0            
Milestone payment ranges         30,000,000.0            
Upfront payment under license agreements         $ 6,000,000.0            
Maximum period to receive royalties         12 years            
Tesaro | Collaborative Arrangement, Product                      
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                      
Milestone revenue recognized           $ 0 $ 10,000,000.0 $ 0      
Pharmsynthez                      
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                      
Ownership percentage           9.00%     9.00% 9.00%  
RXi Pharmaceuticals Corporation                      
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                      
Milestone payments                     $ 50,000,000.0
Accrued Expenses | Pfizer | Collaborative Arrangement, Product                      
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                      
Deferred revenue, current           $ 60,600,000     $ 60,600,000 $ 60,600,000  
Other Long-term Liabilities | Pfizer | Collaborative Arrangement, Product                      
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                      
Deferred revenue, noncurrent           $ 22,500,000     $ 22,500,000 $ 22,500,000  
Minimum | Pfizer | Collaborative Arrangement, Product                      
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                      
Milestone payment ranges       20,000,000.0              
Maximum | Pfizer | Collaborative Arrangement, Product                      
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                      
Milestone payment ranges       $ 90,000,000.0              
Phase Two Initiation                      
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                      
Additional milestone payments 6,000,000                    
Regulatory And Development                      
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                      
Additional milestone payments 31,000,000                    
Sales Revenue                      
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                      
Additional milestone payments $ 75,000,000